Author: Choi, Kang-Seuk
Title: Newcastle disease virus vectored vaccines as bivalent or antigen delivery vaccines Document date: 2017_7_26
ID: vk59ghjm_10
Snippet: NDV vaccine strains infect many mammals but are very safe due to restricted host tropism. Nevertheless, NDV is a strong stimulator of humoral and cellular immune responses at both the local and systemic levels; it also has an adjuvant effect [8] . Importantly, NDV is antigenically distinct from known paramyxoviruses that infect mammals; thus it is unlikely to be affected by pre-existing immunity in mammals [8] . NDV does not establish persistent .....
Document: NDV vaccine strains infect many mammals but are very safe due to restricted host tropism. Nevertheless, NDV is a strong stimulator of humoral and cellular immune responses at both the local and systemic levels; it also has an adjuvant effect [8] . Importantly, NDV is antigenically distinct from known paramyxoviruses that infect mammals; thus it is unlikely to be affected by pre-existing immunity in mammals [8] . NDV does not establish persistent infection in animals and humans because it replicates only in the cytoplasm [8] . In addition, the rule of six means that genetic changes (e.g., insertions, deletions, and recombinations) affecting the integrity of the genome are rare [8] . Therefore, NDV vaccine strains are potential virus vectors that can be used to develop antigen delivery vaccines for use in animals and/or humans.
Search related documents:
Co phrase search for related documents- immune response and NDV vaccine strain: 1
- immune response and persistent infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67
- immune response and pre existing immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39
- immune response and systemic local level: 1, 2
- immune response and vaccine strain: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56
- immune response and virus vector: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52
- NDV vaccine and pre existing immunity: 1, 2, 3, 4
- NDV vaccine and systemic local level: 1
- NDV vaccine and vaccine strain: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- NDV vaccine and virus vector: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- NDV vaccine strain and pre existing immunity: 1
- NDV vaccine strain and vaccine strain: 1, 2, 3, 4, 5, 6
- NDV vaccine strain and virus vector: 1
- persistent infection and pre existing immunity: 1
- persistent infection and recombination deletion: 1
- persistent infection and vaccine strain: 1
- persistent infection and virus vector: 1, 2, 3, 4, 5, 6, 7
- pre existing immunity and vaccine strain: 1, 2, 3
- pre existing immunity and virus vector: 1, 2, 3, 4, 5, 6, 7, 8
Co phrase search for related documents, hyperlinks ordered by date